DAX22.258 -1,3%ESt505.279 -0,8%Top 10 Crypto11,82 -2,8%Dow41.990 ±-0,0%Nas17.450 +0,9%Bitcoin78.177 -0,9%Euro1,0797 ±0,0%Öl74,24 -0,4%Gold3.131 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T Rheinmetall 703000 NVIDIA 918422 RENK RENK73 thyssenkrupp 750000 Novo Nordisk A3EU6F Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Commerzbank CBK100 HENSOLDT HAG000 Volkswagen (VW) vz. 766403 Amazon 906866 Deutsche Telekom 555750 Xiaomi A2JNY1 Siemens Energy ENER6Y
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Warten auf Trumps Zollpaket: DAX rutscht ab -- Asiens Börsen uneins -- FMC platziert Anleihen in Milliardenvolumen -- Volkswagen verbessert US-Absatz deutlich -- Mercedes-Benz,Tesla, Palantir im Fokus
Top News
Continental-Aktie im Minus: Umsatzrückgang im Automotive-Geschäft im ersten Quartal erwartet Continental-Aktie im Minus: Umsatzrückgang im Automotive-Geschäft im ersten Quartal erwartet
NORMA-Aktie nach Quirin-Abstufung unter Druck NORMA-Aktie nach Quirin-Abstufung unter Druck
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Ionis Pharmaceuticals Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
25,04 EUR -2,63 EUR -9,50 %
FSE
27,48 USD +0,22 USD +0,81 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.4,02 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2ACMZ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4622221004

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIONS

Ionis Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireIonis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports fourth quarter and full year 2022 financial results
PR NewswireIonis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
PR NewswireIonis to hold fourth quarter and full year 2022 financial results webcast
PR NewswireIonis announces GSK has advanced bepirovirsen into Phase 3 development
PR NewswireIonis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
PR NewswireIonis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
PR NewswireIonis to present at 41st Annual J.P. Morgan Healthcare conference
PR NewswireIonis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
PR NewswireIonis partners with Metagenomi to add gene editing to its broad technology platform
PR NewswireIonis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports third quarter financial results
PR NewswireIonis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
PR NewswireIonis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
PR NewswireIonis announces positive results from fesomersen development program
PR NewswireIonis to hold third quarter 2022 financial results webcast
PR NewswireIonis announces plan for new manufacturing facility in Oceanside, Calif.
PR NewswireIonis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
PR NewswireIonis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
PR NewswireIonis to present at upcoming investor conferences
PR NewswireIonis reports second quarter financial results and recent business achievements
PR NewswireIonis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
PR NewswireIonis to hold second quarter 2022 financial results webcast
PR NewswireIonis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
PR NewswireIonis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
PR NewswireIonis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference
PR NewswireIonis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
PR NewswireIonis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
PR NewswireIonis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
PR NewswireIonis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
PR NewswireIonis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
PR NewswireIonis to present at RBC Capital Markets Global Healthcare Conference
PR NewswireIonis reports first quarter financial results and recent business achievements
PR NewswireIonis to host 2022 virtual Annual Meeting of Stockholders
PR NewswireIonis to hold first quarter 2022 financial results webcast
PR NewswireIonis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
Wer­bung

Ionis Pharmaceuticals News

Ionis Pharmaceuticals News: auf dieser Seite finden Sie alle Ionis Pharmaceuticals News und Nachrichten zur Ionis Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ionis Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ionis Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.